Evaluating maternal serum sortilin levels: a potential biomarker for predicting preeclampsia

Area of Science:

• Obstetrics and Gynecology
• Cardiovascular Research
• Biomarker Discovery

Background:

• Preeclampsia is a serious pregnancy complication characterized by high blood pressure.
• The underlying mechanisms of preeclampsia pathogenesis are not fully understood.
• Identifying novel biomarkers for preeclampsia is crucial for early diagnosis and management.

Purpose of the Study:

• To investigate the role of sortilin in preeclampsia pathogenesis.
• To examine serum sortilin levels in maternal blood of preeclampsia patients.
• To assess the potential of sortilin as a predictive marker for preeclampsia and adverse neonatal outcomes.

Main Methods:

• A prospective case-control study involving 44 preeclampsia patients and 44 healthy pregnant controls.
• Serum sortilin levels were measured in maternal blood.
• Statistical analysis was performed to compare sortilin levels and assess their correlation with clinical markers and neonatal outcomes.

Main Results:

• Maternal serum sortilin levels were significantly higher in preeclampsia patients compared to controls.
• Sortilin levels demonstrated potential in distinguishing preeclampsia cases (AUC=0.679) and predicting adverse neonatal outcomes (AUC=0.620).
• Elevated sortilin levels correlated significantly with key clinical markers of preeclampsia severity, including AST, ALT, and 24-hour urine protein.

Conclusions:

• Maternal sortilin levels are elevated in preeclampsia.
• Sortilin may serve as a potential biomarker for predicting adverse neonatal outcomes in preeclampsia.
• Sortilin levels are associated with the severity of preeclampsia, correlating with established clinical markers.